Item 8.01. Other Events.
As previously announced, on September 22, 2021, Accelerate Diagnostics, Inc.
(the "Company") entered into a securities purchase agreement (the "Securities
Purchase Agreement") with certain purchasers (collectively, the "Purchasers")
for the issuance and sale by the Company of an aggregate of 3,954,546 shares of
the Company's Series A Preferred Stock, par value $0.001 per share (the "Series
A Preferred Shares"), to the Purchasers in an offering (the "Private Placement")
exempt from registration pursuant to Section 4(a)(2) of the Securities Act of
1933, as amended, and Rule 506 promulgated thereunder.
The Securities Purchase Agreement contemplated that the closing of the Private
Placement would occur in two tranches. The first tranche closed on the date of
the execution of the Securities Purchase Agreement whereby an aggregate of
2,636,364 Series A Preferred Shares were issued and sold to the Purchasers for
aggregate proceeds of approximately $20.3 million. On October 29, 2021, the
Company closed the second tranche of the Private Placement and issued to the
Purchasers an aggregate of 1,318,182 Series A Preferred Shares for aggregate
proceeds of approximately $10.2 million.
For additional information regarding the Private Placement, the Securities
Purchase Agreement and the terms of the Series A Preferred Shares, see the
Current Report on Form 8-K filed with the U.S. Securities and Exchange
Commission on September 23, 2021.
© Edgar Online, source Glimpses
ACCELERATE DIAGNOSTICS, INC. 
